The experience of using the new form of Humira® in children and adolescents with inflammatory bowel diseases in a multidisciplinary pediatric center

Background. It is known that the drug administration way, the physical and chemical properties of the injectable drugs and the physical characteristics of the needles used to injection of the biological drugs play a role in the occurrence of pain during injection associated with the administration of the drug. Objective. Retrospective assessment of the pain during the administration of citrated and citrate-free adalimumab formulations (Humira®) in children with inflammatory bowel diseases, and comparison of the subjective pain intensity with the administration of 40 mg/0.4 ml and 40 mg/0.8 ml adalimumab formulations. Methods. The assessment was carried out in 45 children, 24 boys and 21 girls. The age of the patients ranged from 3.4 to 17.9 years (13.3±3.96). The WAS (0-10 cm) was used for the pain assessment, with 0 - the absence of pain, 10 - intolerable pain. The pain assessment was carried out in the hospital with the injection of adalimumab during the current hospitalization. Results. The use of the citrate-free form of the Humira® with a composition of 40 mg/0.4 ml (concentration 100 mg/ml) demonstrated a decrease in the pain reaction from severe - very severe pain to the absence of pain at the injection site. Conclusion. The use of the citrate-free form of the Humira® preparation with a composition of 40 mg/0.4 ml (concentration 100 mg/ml) demonstrated a decrease in the pain reaction from severe - very severe pain to the absence of pain at the injection site.

inflammatory bowel diseases, Crohn's disease, ulcerative colitis, tumor necrosis factor α, adalimumab